肺耐药蛋白和拓扑异构酶Ⅱ在胆囊癌和胆管癌组织中的表达

Expression of LRP and Topoll in gallbladder carcinoma and cholangiocarcinoma

目的探讨多药耐药（MDR）基因产物肺耐药蛋白（LRP）、DNA拓扑异构酶Ⅱ（TopoⅡ）在胆囊癌和胆管癌中的表达及其与耐药的关系。方法采用免疫组化的方法（IHC）检测18例胆囊癌和36例胆管癌的上述两个指标的表达情况。结果在胆囊癌LRP、IopoⅡ的表达的阳性率分别为77．8％、83．3％，在胆管癌中表达的阳性率为75．0％和91．7％，显著高于对照组的23．1％和30．8％（P〈0．05）。除LRP、FopoⅡ的表达在胆管癌年龄〉60岁组显著高于≤60岁组（P〈0．05）之外．LRP、FopoⅡ与性别、年龄、病理分期、病理类型、分化程度、淋巴结转移无关（P〉0．05）。结论LRP、FopoⅡ在未经化疗的胆囊癌和胆管癌组织中均有不同程度的高表达；胆囊癌和胆管癌的原发性多药耐药与LRP有天，应用TopoⅡ抑制剂治疗可能提高胆道痛的化疗效果。

Objective To investigate the expression of LRP and TopoⅡ, products of MDR gene, in gallbladder carcinoma and cholangiocarcinoma and explore its relation to drug resistance. Methods The expression of LRP and TopoⅡ in gallbladder carcinoma and cholangiocarcinoma was determined with immunohistochemistry. Results The positive rate of expression of the 2 products was 77.8% and 83.3% in gallbladder carcinoma and 7,5.0% and 91. 7% in cbolangiocarcinoma, respectively. They were significantly higher than those of 23.1% and 30.8% in the control group （P〈 0.05）. Conclusion LRP and TopoⅡ have high expression levels in gallbladder carcinoma and cholan gioearcinoma before chemotherapy. The primary MDR of the 2 kinds of carcinoma might be associated with LRP. Using inhibiting agents of TopoⅡ can promote the efficacy of chemotherapy for cholangio carcinoma.